Petition Seeks Immune Monitoring Requirements for Vertex's Povetacicept

A citizen petition filed by Foley & Lardner urges FDA to require mandatory monthly immunoglobulin monitoring and explicit treatment-interruption instructions in the prescribing information for Vertex Pharmaceuticals' investigational IgA nephropathy treatment povetacicept, ahead of an 11/30 user fee review action target date.

The 10/21 petition contends that the safety findings from Vertex's Phase 3 RAINIER trial were obtained under a protocol requiring regular monitoring for hypogammaglobulinemia, a condition involving abnormally low immunoglobulin levels that can increase susceptibility to infection.

It asks FDA to require serum immunoglobulin G (IgG) testing before treatment and every four weeks thereafter, with treatment withheld if IgG falls below 300 mg/dL and permanently discontinued if levels fall below 150 mg/dL on confirmatory testing.

According to the petition, the RAINIER protocol required testing every four weeks through Week 104 and prohibited further active dosing when IgG fell below 300 mg/dL until levels recovered. The petitioner argues that less frequent monitoring in clinical practice could expose patients to additional doses without detecting potentially dangerous reductions in IgG.

Additional concerns involve earlier RUBY-3 trial findings in which five patients with IgA nephropathy developed IgG levels below 300 mg/dL, all after Week 48. None of those cases was associated with serious or severe infection.

The petition argues that these findings support continued monitoring during long-term treatment rather than relaxing surveillance after initially stable laboratory results.

These and other requested labeling requirements would apply if the agency approves povetacicept.